DF/HCC Renal Cancer SPORE

描述(由申请者提供)：本申请是由新成立的Dana-Farber哈佛癌症中心(DF/HCC)和贝丝以色列女执事医疗中心的肾癌发展中项目创建的肾癌卓越研究专业项目。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员--贝丝以色列女执事医疗中心、达纳-法伯癌症研究所、马萨诸塞州总医院、布里格姆妇女医院、儿童医院医疗中心以及哈佛大学公共卫生学院。这一应用支持五个主要项目，包括：1)识别早期发现和监测高危肾癌人群的标志物；2)抑制VHL调节的生长因子通路治疗肾癌；3)联合射频消融和抗血管/无血管生成疗法治疗肾癌；4)鉴定与肾癌预后和治疗反应有关的分子和免疫学相关因素；5)树突状细胞/肿瘤融合和IL-12作为肾癌新的免疫疗法。这些项目由四个核心集成在一起。它们是：1)管理、评估和规划；2)生物统计学；3)组织采集、病理学和临床数据；以及4)监测。这份孢子申请概述了一个发展项目计划，其中包括一个选择和审查项目的计划，以及八个可以考虑支持的样本项目。我们还包括一个职业发展奖励计划，该计划概述了一种识别、支持和审查肾癌领域有才华的年轻研究人员的机制。DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为对肾癌患者具有临床意义的进步。

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.